News
-
Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease
-
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO – Inflammatory Bowel Diseases
-
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
-
Celsius Therapeutics Names Scientific Advisers
-
Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
-
Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022